This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
DermTech Inkomsten in het verleden
Verleden criteriumcontroles 0/6
DermTech's earnings have been declining at an average annual rate of -49.5%, while the Biotechs industry saw earnings growing at 14.7% annually. Revenues have been growing at an average rate of 35.3% per year.
Belangrijke informatie
-49.5%
Groei van de winst
-8.9%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 12.9% |
| Inkomstengroei | 35.3% |
| Rendement op eigen vermogen | -135.8% |
| Nettomarge | -853.0% |
| Laatste winstupdate | 30 Jun 2023 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe DermTech geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 23 | 14 | -120 | 97 | 19 |
| 31 Mar 23 | 14 | -118 | 98 | 22 |
| 31 Dec 22 | 15 | -117 | 95 | 24 |
| 30 Sep 22 | 15 | -115 | 92 | 25 |
| 30 Jun 22 | 14 | -106 | 84 | 24 |
| 31 Mar 22 | 13 | -93 | 75 | 20 |
| 31 Dec 21 | 12 | -78 | 62 | 16 |
| 30 Sep 21 | 11 | -63 | 50 | 12 |
| 30 Jun 21 | 9 | -52 | 41 | 9 |
| 31 Mar 21 | 7 | -45 | 35 | 7 |
| 31 Dec 20 | 6 | -36 | 30 | 5 |
| 30 Sep 20 | 5 | -31 | 27 | 4 |
| 30 Jun 20 | 5 | -27 | 24 | 3 |
| 31 Mar 20 | 4 | -21 | 19 | 3 |
| 31 Dec 19 | 3 | -20 | 15 | 2 |
| 30 Sep 19 | 2 | -18 | 12 | 2 |
| 30 Jun 19 | 2 | -14 | 8 | 2 |
| 31 Mar 19 | 3 | -13 | 7 | 2 |
| 31 Dec 18 | 2 | -10 | 6 | 2 |
| 31 Dec 17 | 2 | -8 | 6 | 2 |
| 30 Jun 14 | 0 | -6 | 2 | 3 |
| 31 Mar 14 | 0 | -6 | 2 | 2 |
| 31 Dec 13 | 0 | -5 | 1 | 2 |
Kwaliteitswinsten: DMTK * is currently unprofitable.
Groeiende winstmarge: DMTK * is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: DMTK * is unprofitable, and losses have increased over the past 5 years at a rate of 49.5% per year.
Versnelling van de groei: Unable to compare DMTK *'s earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: DMTK * is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-9.8%).
Rendement op eigen vermogen
Hoge ROE: DMTK * has a negative Return on Equity (-135.82%), as it is currently unprofitable.